Coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa
Inventors
Narain, Niven Rajin • Sarangarajan, Rangaprasad • Kiebish, Michael Andrew
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12616666-B2
Publication Date
2026-05-05
Expiration Date
Abstract
The present invention is directed, in part, to methods of treating Epidermolysis Bullosa (EB) in a subject in need thereof, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of a of Coenzyme Q10 (CoQ10) to the subject.
Core Innovation
The disclosed invention concerns treating Epidermolysis Bullosa in a subject having associated wounds by topically administering a pharmaceutical composition containing a therapeutically effective amount of Coenzyme Q10. The claim links this topical administration directly to a reduction in wound size. This reduction in wound size serves as the principal treatment outcome stated in the claim.
The disclosure describes wound-healing progression, skin structural-protein expression, and clinical lesion photographs demonstrating wound-size reduction and re-epithelialization across Epidermolysis Bullosa subtypes. Documented evaluations include serial photographic assessments of lower-leg wounds over weekly intervals alongside changes in wound inflammation, granulation, and collagen organization. The disclosure additionally describes Coenzyme Q10-associated effects on cell number and protein expression in SK-MEL-28 and HASMC cells.
Claims Coverage
The claims identify independent claim coverage comprising two inventive features directed to treating Epidermolysis Bullosa-associated wounds.
Topical Coenzyme Q10 administration for Epidermolysis Bullosa wounds
The claim recites topically administering to a subject with Epidermolysis Bullosa-associated wounds a pharmaceutical composition comprising a therapeutically effective amount of Coenzyme Q10.
Reduction in wound size
The claim specifies that topically administering the pharmaceutical composition reduces the size of the Epidermolysis Bullosa-associated wounds.
The independent claim combines topical administration of a therapeutically effective amount of a Coenzyme Q10 composition with achieving wound-size reduction in subjects having Epidermolysis Bullosa.
Stated Advantages
The claimed treatment reduces the size of wounds associated with Epidermolysis Bullosa.
Documented Applications
Topical Coenzyme Q10 treatment of wounds associated with Epidermolysis Bullosa in a subject.
Interested in licensing this patent?